CD147, considered to have a potential proatherosclerotic effect (Wang et al., 2015), is upregulated in COVID-19 patients and can act as a receptor for SARS-CoV-2 in cells expressing low ACE2 (Radzikowska et al., 2020). This evidence concerns the gene ACE2 and COVID-19.